Nutex Health Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Für Nutex Health wird ein Gewinn- und Umsatzwachstum von 31.2% bzw. 6% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 23.6% pro Jahr steigen soll.
Wichtige Informationen
31.2%
Wachstumsrate der Gewinne
23.61%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 19.0% |
| Wachstumsrate der Einnahmen | 6.0% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 02 Jun 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • Jun 04
NUTX: Low EV EBITDA Multiple Will Support Future Upside Potential
Analysts have raised their Nutex Health fair value estimate from $221.67 to $235.50, citing what they describe as a relatively low ~3x EV/EBITDA multiple and limited prior coverage of the stock as key reasons for the higher $235 price target. What's in the News No recent company specific news, periodical coverage, or key developments were identified in the provided sources for Nutex Health.
Narrativ-Update • May 09
NUTX: Share Repurchases Will Support Future Margins And Upside Potential
Analysts now place Nutex Health's fair value at $175.00, up from $150.00, citing updated assumptions around revenue growth of 5.25%, a profit margin of 21.15%, a discount rate of 7.19% and a forward P/E of 7.95. What's in the News On March 5, 2026, the Board of Directors authorized a share buyback plan for Nutex Health.Narrativ-Update • Apr 23
NUTX: Share Repurchases Will Support Future Margins And Undervalued Upside
Analysts reaffirm a $150.00 price target for Nutex Health, citing updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a small change in future P/E multiples as key inputs to their valuation work. What's in the News Nutex Health Inc.Narrativ-Update • Apr 09
NUTX: New Buyback Program Will Support Future Margin Resilience
Analysts have raised their Nutex Health price target to $150.00 as they now factor in slightly stronger revenue growth, a modestly higher profit margin of about 18.6%, and a marginally lower future P/E assumption near 8x. What's in the News From October 1, 2025 to December 31, 2025, Nutex Health repurchased 27,870 shares, about 0.4% of its stock, for US$4.95 million under a previously announced buyback program (Key Developments).Narrativ-Update • Mar 25
NUTX: Share Repurchases Will Support Future Upside Potential
Analysts have adjusted their price target on Nutex Health from $241.67 to $221.67, reflecting updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Nutex Health completed a previously announced buyback program, repurchasing 27,870 shares, representing 0.4% of the company, for a total of $4.95 million between October 1, 2025 and December 31, 2025 (Key Developments).Narrativ-Update • Mar 11
NUTX: New Hospitals And Buybacks Will Support Future Margin Resilience
Analysts have adjusted their price target on Nutex Health to $150 from $220, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Nutex Health Inc.Narrativ-Update • Feb 25
NUTX: Expanded Hospital Footprint Will Support Future Margin Resilience
Analysts have kept their $220.00 price target for Nutex Health unchanged, citing relatively steady assumptions for the discount rate, long-term revenue growth, profit margin, and future P/E expectations. What's in the News Nutex Health announced the opening of its 26th hospital, Archview ER & Hospital, in a new state, Missouri, expanding its footprint into St. Louis for the first time (Key Developments).Narrativ-Update • Feb 11
NUTX: Future Margin Resilience Will Outlast Fraud Allegations And Filing Delay
Analysts have maintained their Nutex Health fair value estimate at $220.00. They cite small adjustments to the discount rate, revenue growth, profit margin, and expected future P/E assumptions, rather than any major change in their overall view.Narrativ-Update • Jan 27
NUTX: Future Margin Strength Will Outweigh Fraud Allegation And Filing Risk
Analysts have kept their price target on Nutex Health steady at US$220.00, citing slightly higher modeled revenue growth, a modestly improved profit margin and a marginally lower forward P/E assumption as key reasons for maintaining their view. What's in the News Short seller Capybara Research published a report alleging that Nutex Health and its founder CEO engaged in fraudulent and unethical business practices, citing interviews with former insiders and partners and claiming a pattern of misconduct over about 10 years (Periodical).Narrativ-Update • Jan 12
NUTX: Future Margin Strength Will Offset Fraud Allegation Headwinds
Analysts have slightly revised their price target on Nutex Health to US$220, reflecting modestly updated assumptions around revenue, profit margins, and future P/E expectations. What's in the News Capybara Research published a report alleging Nutex Health and its CEO engaged in fraudulent and unethical business practices over a period of about 10 years.Narrativ-Update • Dec 26
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Analysts have modestly raised their price target on Nutex Health to approximately 220 dollars per share, citing slightly stronger anticipated revenue growth and profit margins. These factors support a marginally lower future price to earnings multiple.Narrativ-Update • Dec 12
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Narrative Update on Nutex Health Analysts have raised their price target on Nutex Health from 205.00 dollars to 220.00 dollars, reflecting expectations for meaningfully improved profit margins and a more favorable future earnings multiple, despite moderating revenue growth assumptions and a slightly lower discount rate. What's in the News Capybara Research issued a report alleging Nutex Health and its CEO engaged in a long running pattern of fraudulent and unethical business practices, and warned that more physician groups and emergency rooms may sever ties with the company (Capybara Research report).Seeking Alpha • Sep 10
Nutex: Diagnosed With A Case Of Fair Value
Summary Nutex Health shows strong revenue growth and a healthy balance sheet, but recent issues with SEC filings and a short report caused the stock to decline. Growth prospects hinge on the execution of expansion, especially in the IPA segment, which could drive future cash flow at low cost. Competitive pressures, cyclical capex, and significant stock-based compensation limit upside and warrant a deeper margin of safety for investors. At current levels, NUTX is not undervalued; I recommend a Hold rating and would only consider buying below $65 for better risk-reward. Read the full article on Seeking AlphaNeues Narrativ • May 28
Aging US Population Will Drive Micro-Hospital Expansion Despite Payer Challenges
Expansion in key markets and value-focused care models align Nutex with demographic trends and rising demand for accessible, cost-effective healthcare.Analyseartikel • Jan 24
Health Check: How Prudently Does Nutex Health (NASDAQ:NUTX) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Dec 25
Nutex Health Inc. (NASDAQ:NUTX) Might Not Be As Mispriced As It Looks
When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...Analyseartikel • Aug 12
Nutex Health Inc. (NASDAQ:NUTX) Just Reported, And Analysts Assigned A US$2.75 Price Target
The analysts might have been a bit too bullish on Nutex Health Inc. ( NASDAQ:NUTX ), given that the company fell short...Analyseartikel • Apr 17
Nutex Health Inc.'s (NASDAQ:NUTX) 30% Cheaper Price Remains In Tune With Revenues
Unfortunately for some shareholders, the Nutex Health Inc. ( NASDAQ:NUTX ) share price has dived 30% in the last thirty...Seeking Alpha • Aug 23
Nutex Health GAAP EPS of -$0.03, revenue of $58.05M
Nutex Health press release (NASDAQ:NUTX): Q2 GAAP EPS of -$0.03. Revenue of $58.05M (-7.6% Y/Y). Adjusted EBITDA of $9.4M. As of June 30, 2022, the company had total assets of $871.8M, including cash and cash equivalents of $47.6M.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2027 | 972 | 177 | 12 | 47 | 4 |
| 12/31/2026 | 881 | 156 | 9 | 39 | 4 |
| 3/31/2026 | 880 | 96 | 265 | 273 | N/A |
| 12/31/2025 | 875 | 71 | 241 | 248 | N/A |
| 9/30/2025 | 981 | 121 | 174 | 178 | N/A |
| 6/30/2025 | 792 | 56 | 81 | 85 | N/A |
| 3/31/2025 | 624 | 74 | 69 | 71 | N/A |
| 12/31/2024 | 480 | 52 | 21 | 23 | N/A |
| 9/30/2024 | 292 | -41 | 20 | 21 | N/A |
| 6/30/2024 | 276 | -38 | 13 | 17 | N/A |
| 3/31/2024 | 259 | -41 | -3 | 3 | N/A |
| 12/31/2023 | 248 | -46 | -8 | 1 | N/A |
| 9/30/2023 | 232 | -29 | 5 | 8 | N/A |
| 6/30/2023 | 197 | -436 | -7 | -2 | N/A |
| 3/31/2023 | 196 | -451 | 6 | 16 | N/A |
| 12/31/2022 | 219 | -425 | 36 | 51 | N/A |
| 9/30/2022 | 229 | -396 | 58 | 93 | N/A |
| 6/30/2022 | 319 | 70 | 92 | 124 | N/A |
| 3/31/2022 | 336 | 122 | 123 | 158 | N/A |
| 12/31/2021 | 332 | 133 | 137 | 173 | N/A |
| 9/30/2021 | 374 | 159 | 94 | 160 | N/A |
| 12/31/2020 | 274 | 106 | 25 | 87 | N/A |
| 12/31/2019 | 97 | 21 | N/A | 12 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: NUTXDas prognostizierte Gewinnwachstum (31.2% pro Jahr) liegt über der Sparquote (3.5%).
Ertrag vs. Markt: NUTXDie Erträge des Unternehmens (31.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (17.1% pro Jahr).
Hohe Wachstumserträge: NUTXEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: NUTXDie Einnahmen des Unternehmens (6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.9% pro Jahr).
Hohe Wachstumseinnahmen: NUTXDie Einnahmen des Unternehmens (6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NUTX in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/09 07:17 |
| Aktienkurs zum Tagesende | 2026/06/09 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Nutex Health Inc. wird von 5 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| William Sutherland | Benchmark Company |
| Eugene Mannheimer | Freedom Capital Markets |
| Benjamin Haynor | Lake Street Capital Markets, LLC |